2023-11-17 08:01:25 ET
- Novavax ( NASDAQ: NVAX ) on Friday announced changes to its leadership team and named John Trizzino to the new role of president and chief operating officer.
- In the newly created role, Trizzino will lead commercial; chemistry, manufacturing and controls; and regulatory functions of the company. He was previously executive vice president, chief business officer and chief commercial officer at Novavax.
- In addition, Mark Casey will join the company as its new chief legal officer and corporate secretary, taking over from December 11 from John Herrmann, who is set to retire on December 8.
- CEO John Jacobs said: "As we announced last week , we are keenly focused on effectively delivering our COVID-19 product to market and evolving Novavax's scale and structure to position the company for future success. In his new role as chief operating officer, John Trizzino will focus on all aspects of successful product delivery, both for the 2023-2024 vaccination season and beyond."
- Novavax ( NVAX ) expects COVID-19 vaccine uptake in the U.S. to reach 30M–50M doses during the 2023–2024 season and said its updated vaccine is available at about 14K pharmacy locations nationwide.
For further details see:
Novavax updates leadership structure, names COO